ProductsDistribution Products


Therapeutic indication:

Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure.HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start.The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis.

  • Composition: Hepatitis B Immunoglobulin human 500 IU
  • Pharmaceutical form: Solution for injection
  • Method of administration: Subcutaneous
  • Manufacturer: Biotest